Page 131 of 291 · 8,722 total

patent instituted · Jan 5, 2025

AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.

· IPR2025-00949

AZURITY PHARMACEUTICALS successfully convinced the PTAB that multiple claims of Helsinn Healthcare's anti-emetic patent were unpatentable. The Board granted institution based on obviousness (103) over several prior art references, paving the way for a full trial.

patent instituted · Jan 5, 2025

AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.

· IPR2025-00948

AZURITY PHARMACEUTICALS successfully petitioned to institute IPR against Helsinn Healthcare's '515 patent covering anti-emetic agents. The Board found a reasonable likelihood of prevailing based on obviousness (103) and prior art, allowing the challenge to proceed.

patent instituted · Jan 5, 2025

AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.

· IPR2025-00947

AZURITY PHARMACEUTICALS successfully convinced the PTAB to institute IPR proceedings against Helsinn Healthcare S.A.'s patent covering anti-emetic agents for oncology treatment. The Board found a reasonable likelihood that numerous claims would be unpatentable under 35 U.S.C. § 103 based on prior art references.

patent instituted · Jan 5, 2025

AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.

· IPR2025-00945

AZURITY PHARMACEUTICALS successfully petitioned to institute IPR proceedings against Helsinn Healthcare S.A.'s anti-emetic patent (8623826). The Board found a reasonable likelihood of prevailing on independent claim 19, allowing the challenge based on obviousness over prior art like MASCC and Hoffmann.

patent instituted · Jan 5, 2025

AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.

· IPR2025-00946

AZURITY PHARMACEUTICALS, INC. successfully secured institution of its IPR against Helsinn Healthcare S.A.'s patent (9186357) for anti-emetic agents. The Board found a reasonable likelihood that several claims would be unpatentable over prior art, specifically regarding the combination of triple-drug CINV treatment and superior NK antagonists.

patent instituted · Jan 5, 2025

Samsung Electronics Co., Ltd. et al. v.Wilus Institute of Standards and Technology Inc.

· IPR2025-00934

Samsung challenged Wilus's wireless patent claims based on obviousness in view of prior art standards and publications. The PTAB institution decision found a reasonable likelihood that the claims are unpatentable, specifically citing combinations of Bharadwaj and Sun. This sets up a significant trial over HE WLAN technology.

patent instituted · Jan 5, 2025

Apple Inc. v.Apex Beam Technologies LLC

· IPR2025-00905

Apple Inc. successfully secured the institution of Inter Partes Review against Apex Beam Technologies LLC's patent, challenging 17 claims based on obviousness over prior art including Yeo and TS36.

patent instituted · Jan 5, 2025

Apple Inc. v.Apex Beam Technologies LLC

· IPR2025-00898

Apple successfully secured the institution of an IPR against Apex Beam Technologies, challenging 20 claims related to massive MIMO transmission. The Board found a reasonable likelihood of prevailing based on obviousness over prior art references Kim and Chen.

patent instituted · Jan 5, 2025

Apple Inc. v.Apex Beam Technologies LLC

· IPR2025-00894

Apple successfully secured the institution of Inter Partes Review against Apex Beam's patent 10,462,767, challenging all 20 claims based on obviousness over prior art standards like Yeo and TS36.

patent instituted · Jan 5, 2025

Google LLC v.Sandpiper CDN, LLC

· IPR2025-00860

Google LLC initiated an IPR against Sandpiper CDN, LLC's patent (10924573) covering Content Delivery Networks. The Board instituted the case, finding a reasonable likelihood that Google could prevail under 35 U.S.C. § 103 based on obviousness over prior art combinations.

patent denied · Jan 5, 2025

Docker Inc. v.Intellectual Ventures II LLC

· IPR2025-00840

The USPTO Board denied the institution of IPR2025-00840, favoring Intellectual Ventures II LLC's request for discretionary denial. The decision cited parallel district court and IPR proceedings as reasons to conserve resources.

patent terminated or settled · Jan 4, 2025

Shenzhen Fbtech Electronics Ltd. et al. v.LithiumHub Technologies, LLC

· IPR2025-00822

Shenzhen FBTech and LiTime settled their IPR against LithiumHub's battery‑technology patent before trial, prompting the PTAB to terminate the proceeding and keep the settlement confidential.

patent terminated or settled · Jan 4, 2025

Shenzhen Fbtech Electronics Ltd. et al. v.LithiumHub Technologies, LLC

· IPR2025-00822

Shenzhen Fbtech and Shenzhen Litime reached a settlement with LithiumHub Technologies, filing a joint motion to terminate IPR2025-00822 under 35 U.S.C. § 317.

patent · Jan 4, 2025

Shenzhen Fbtech Electronics Ltd. et al. v.LithiumHub Technologies, LLC

· IPR2025-00822

Shenzhen FBTech, Shenzhen Litime and LithiumHub Technologies filed a joint motion asking the PTAB to treat their settlement agreements as business‑confidential information, invoking statutory authority for confidentiality.

patent terminated or settled · Jan 4, 2025

Inter IKEA Systems B.V. v.POINTWISE VENTURES, LLC

· IPR2025-00798

Inter IKEA Systems and Pointwise Ventures settled their dispute over U.S. Patent 8,471,812, leading the PTAB to terminate the IPR before institution. The settlement agreement was ordered to be kept confidential under 37 C.F.R. § 42.74.

patent · Jan 4, 2025

Shenzhen Fbtech Electronics Ltd. et al. v.LithiumHub Technologies, LLC et al.

· IPR2025-00825

Petitioners and the patent owner jointly filed a motion asking the PTAB to treat their settlement agreements as business confidential information, invoking 35 U.S.C. §317(b) and 37 C.F.R. §42.74(c). The request is presented as timely and compliant with the applicable statutes and regulations.

patent terminated or settled · Jan 4, 2025

Shenzhen Fbtech Electronics Ltd. et al. v.LithiumHub Technologies, LLC et al.

· IPR2025-00825

The parties to IPR2025‑00825 settled their dispute over U.S. Patent 9,412,994 and jointly moved to terminate the inter partes review. The Board has not yet ruled on institution, and the motion cites statutory authority for termination.

patent terminated or settled · Jan 4, 2025

Shenzhen Fbtech Electronics Ltd. et al. v.LithiumHub Technologies, LLC

· IPR2025-00822

LithiumHub Technologies and two Shenzhen firms settled IPR2025‑00822 concerning a solid‑state lithium battery patent, seeking dismissal of the proceeding.

patent · Jan 4, 2025

Inter IKEA Systems B.V. v.POINTWISE VENTURES, LLC

· IPR2025-00798

IKEA and Pointwise jointly filed a motion requesting that their settlement agreement in IPR2025-00798 be treated as business confidential information, invoking 35 U.S.C. § 317(b). The Board’s decision on the confidentiality request is pending.

patent terminated or settled · Jan 4, 2025

Inter IKEA Systems B.V. v.POINTWISE VENTURES, LLC

· IPR2025-00798

Inter IKEA Systems and Pointwise Ventures jointly moved to terminate IPR2025-00798 after settling their dispute over U.S. Patent 8,471,812. The Board is asked to dismiss the proceeding per settlement and statutory provisions.

patent terminated or settled · Jan 4, 2025

Shenzhen Fbtech Electronics Ltd. et al. v.LithiumHub Technologies, LLC et al.

· IPR2025-00825

LithiumHub Technologies and Shenzhen FBTech settled their IPR dispute over U.S. Patent 9,412,994, seeking Board approval to dismiss the proceeding.

patent denied · Jan 4, 2025

Zhuhai CosMX Battery Co., Ltd. v.Ningde Amperex Technology Ltd.

· IPR2025-00722

The PTAB denied Zhuhai CosMX Battery’s petition to invalidate Ningde Amperex’s 2020 electrolyte patent, finding no reasonable likelihood of success. The Board held that the prior art did not adequately disclose all claim elements, especially the propyl propionate ratio.

patent terminated or settled · Jan 4, 2025

Shenzhen Fbtech Electronics Ltd. et al. v.LithiumHub Technologies, LLC et al.

· IPR2025-00825

Shenzhen FBTech and LiTime settled their IPR challenge to LithiumHub's patent 9,412,994, leading the PTAB to terminate the proceeding before trial and keep the settlement confidential.

patent · Jan 4, 2025

Amphenol Corporation v.Credo Technology Group Ltd.

· IPR2025-00607

Court decision.

patent terminated or settled · Jan 4, 2025

Amphenol Corporation v.Credo Technology Group Ltd.

· IPR2025-00607

Amphenol and Credo Technology settled four inter partes review proceedings, leading the PTAB to terminate the cases before trial.

patent terminated or settled · Jan 4, 2025

Amphenol Corporation v.Credo Technology Group Ltd.

· IPR2025-00607

Amphenol and Credo have settled the IPR concerning U.S. Patent 11,495,898 and jointly filed a motion to keep the settlement agreement confidential, seeking termination of the proceeding.

patent · Jan 4, 2025

Samsung Electronics Co., Ltd. et al. v.GenghisComm Holdings, LLC

· IPR2025-00788

Samsung has filed an IPR petition challenging 16 claims of GenghisComm’s ’568 patent, asserting anticipation and obviousness over multiple prior‑art references and arguing the patent is post‑AIA. The petition seeks institution of the review.

patent · Jan 4, 2025

Zhuhai CosMX Battery Co., Ltd. v.Ningde Amperex Technology Ltd.

· IPR2025-00722

Zhuhai CosMX Battery challenges Ningde Amperex’s 11,799,131 patent covering lithium‑ion battery electrolytes and electrode structures, seeking cancellation of claims 14‑17 on obviousness grounds.

patent · Jan 4, 2025

Inter IKEA Systems B.V. v.POINTWISE VENTURES, LLC

· IPR2025-00798

Inter IKEA Systems petitions the PTAB to invalidate claims 1‑12 of Pointwise Ventures’ ’812 patent, arguing anticipation by Darrell and obviousness over Boncyk, Darrell, and Fukuda.

patent · Jan 4, 2025

Shenzhen Fbtech Electronics Ltd. et al. v.LithiumHub Technologies, LLC et al.

· IPR2025-00825

Chinese challengers have filed an IPR petition seeking cancellation of all 23 claims of LithiumHub’s ‘994 starter‑battery patent, arguing obviousness over six prior‑art references and urging the Board to institute the review.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →